Recent Quotes (30 days)

You have no recent quotes
chg | %

Novartis AG (ADR)  

(Public, NYSE:NVS)   Watch this stock  
Find more results for NVS
74.97
+0.14 (0.19%)
Real-time:   3:03PM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 74.85 - 75.11
52 week 66.93 - 83.58
Open 74.86
Vol / Avg. 1.38M/2.94M
Mkt cap 194.76B
P/E 26.80
Div/yield 2.75/3.66
EPS 2.80
Shares 2.37B
Beta 0.77
Inst. own 10%
Feb 28, 2017
Novartis AG Annual Shareholders Meeting
Jan 25, 2017
Novartis AG R&D Update Corporate Analyst Meeting
Jan 25, 2017
Q4 2016 Novartis AG Earnings Release
Jan 25, 2017
Q4 2016 Novartis AG Earnings Call
Jan 9, 2017
Novartis AG at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin 7.43% 13.55%
Operating margin 11.54% 16.74%
EBITD margin - 28.27%
Return on average assets 2.84% 5.12%
Return on average equity 5.12% 8.84%
Employees 118,393 -
CDP Score - 98 B

Address

Lichtstrasse 35
BASEL, 4056
Switzerland
+41-61-3241111 (Phone)
+41-61-3247826 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Officers and directors

Joseph Jimenez Chief Executive Officer, Member of the Executive Committee
Age: 57
Bio & Compensation  - Reuters
Harry Kirsch Chief Financial Officer, Member of the Executive Committee
Age: 51
Bio & Compensation  - Reuters
Michael Ball Chief Executive Officer of Alcon, Member of the Executive Committee
Bio & Compensation  - Reuters
James Bradner M.D. President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
Bio & Compensation  - Reuters
Richard D. Francis Chief Executive Officer of Sandoz Division, Member of the Executive Committee
Age: 48
Bio & Compensation  - Reuters
Paul Hudson Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
Bio & Compensation  - Reuters
Bruno Strigini Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
Bio & Compensation  - Reuters
Felix R. Ehrat Ph.D. Group General Counsel, Member of the Executive Committee
Age: 60
Bio & Compensation  - Reuters
Steven Baert Head of Human Resources, Member of the Executive Committee
Age: 42
Bio & Compensation  - Reuters
Vasant Narasimhan M.D. Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee
Bio & Compensation  - Reuters